Company intelligence / Profile preview

SQ Innovation, Inc.

Ownership: Private
Employees: ~1
Development stage: NDA

Overview

Lasix ONYU, a novel high-concentration furosemide formulation delivered via an on-body infusor device for at-home treatment of fluid overload in chronic heart failure patients, received Tentative FDA Approval in late 2024. Full approval and commercial launch are expected after the expiration of exclusivity for a competing product.[6][8] Clinical results indicate comparable efficacy to IV administration with the benefit of at-home use.

Therapeutic areas: OtherCardiovascular
Modalities: Small molecules (furosemide/Lasix)Drug-device combination products
Industry: Biotech

Drug pipeline

1 asset

SQIN-furosemide

Partnerships

Gerresheimer AG – design/manufacturing partner for the on-body drug delivery device used with Lasix ONYU

Beyond the preview

Go deeper on SQ Innovation, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SQ Innovation, Inc..

Explore the full profile